Aura Biosciences (AURA) Company Future Sales Volume

Aura Biosciences Inc - graphic logo of issuer AURA

Aura Biosciences, Inc. (AURA) develops targeted drugs for ocular oncology therapy, ensuring high margins while adhering to chemical disposal standards. Projected sales revenues confirm the financial potential, where 0.00 serves as the final level mark. However, fierce patent battles and advancements in genetic engineering create significant risks for the company's market positions.

Company Future Revenue: Aura Corp (AURA) for 07/04/2022 - 11/19/2026

Financial and market metric breakdowns for Aura Bio (AURA)

- market capitalization details:
General company analysis:Aura Biosciences Inc
Product sample of Aura Biosciences Inc

Expected sales volume reflects a temporary business discount relative to its fundamental potential, capturing periods of asset accumulation before the valuation gap is closed. The current calculated level of 0.00 at the target product realization level measures the market undervaluation of future cash flows, which are expected to be generated by the innovations of leading ophthalmic oncologists and their advanced laboratory infrastructure for Aura Biosciences, Inc. (AURA).

Main competitors

Projected Sales Volume ONC|HALO (Halozyme) - Company Future Revenue|Projected Sales Volume RVMD (revmed.com)|Company Future Sales Ascentage (AAPG)|CGON: Company Future Sales Volume|Company Expected Sales Volume UroGen Pharma Ltd.|BCAX: Projected Sales Volume|PSNL - Company Future Sales|ERAS (Erasca Oncology) - Projected Sales Volume|Projected Sales Volume Delcath Systems, Inc.|Company Projected Revenue ymabs.com (YMAB)|Company Projected Revenue CADL (Candel)|Accuray, Inc. - Company Future Sales Volume|SELLAS Life Sciences Group Inc. - Company Projected Revenue|ACTU: Company Future Sales Volume|Company Expected Sales Volume Citius Oncology Inc|HURA: Projected Sales Volume|TARA: Company Projected Revenue Volume|FATE (fatetherapeutics.com) - Projected Sales Volume|Company Future Sales Volume Aadi Bioscience Inc (WHWK)|Projected Sales Volume TCRX|CSBR - Company Expected Sales Volume|Projected Sales Volume XBIT (XBiotech Inc.)|CEL-SCI Corporation (CVM) - Company Expected Sales Volume|OSTX: Company Future Sales Volume|Company Future Revenue RADX (Radiopharm Theranostics)|Artiva (ARTV) - Company Projected Revenue|ANL: Company Projected Revenue Volume|VERU (Veru Corporation) - Projected Sales Volume|Company Expected Sales Volume Tempest Therapeutics, Inc. TPST|Projected Sales Volume XLO|Renovaro - Company Revenue Forecast|Company Projected Revenue Mural Bio MURA|KAPA: Company Revenue Forecast|OnKure Therapeutics - Projected Sales Volume|Company Future Sales w2.cytomed.sg GDTC|CRIS: Projected Sales Volume|Company Future Sales Volume Apollomics Inc.|THAR (Tharimmune Corporation) - Projected Sales Volume|Projected Sales Volume Advanced Biomed Inc|Projected Sales Volume GNPX|Company Future Sales Volume Calidi Biotherapeutics Inc. CLDI|Company Projected Revenue Sunshine Biopharma Inc. SBFM|Company Future Sales Xenetic Biosciences (XBIO)|SLRX - Company Projected Revenue|Company Expected Sales Volume Kitov Pharma|AON (AONC) - Company Projected Revenue|Company Future Sales Volume BeiGene|Company Projected Revenue checkpointtx.com|Company Revenue Forecast ELEV (Elevation Oncology)|Projected Sales Volume ICAD|Ikena Oncology - Company Revenue Forecast|Company Projected Revenue Notable Labs, Ltd. NTBL|VIRX: Company Revenue Forecast|MOR - Company Projected Revenue|NAYA Bio (NAYA) - Company Future Sales Volume|AAPGV: Projected Sales Volume